EyePoint Pharmaceuticals (NASDAQ:EYPT) had its price target increased by stock analysts at B. Riley from $5.00 to $8.50 in a research note issued to investors on Tuesday, The Fly reports. The firm currently has a “buy” rating on the stock. B. Riley’s price objective suggests a potential downside of 17.64% from the stock’s previous close.
EYPT has been the subject of several other reports. BidaskClub lowered shares of EyePoint Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 9th. Zacks Investment Research raised shares of EyePoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Wednesday, December 23rd. ValuEngine upgraded shares of EyePoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, December 11th. Finally, HC Wainwright upgraded EyePoint Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Friday, October 9th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $11.17.
NASDAQ:EYPT opened at $10.32 on Tuesday. EyePoint Pharmaceuticals has a 1 year low of $3.51 and a 1 year high of $21.00. The stock’s fifty day moving average price is $5.99 and its two-hundred day moving average price is $5.76. The company has a debt-to-equity ratio of 6.69, a current ratio of 3.68 and a quick ratio of 3.40. The company has a market cap of $148.11 million, a P/E ratio of -3.04 and a beta of 1.51.
EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.30). EyePoint Pharmaceuticals had a negative return on equity of 434.26% and a negative net margin of 112.23%. The company had revenue of $15.70 million for the quarter, compared to analyst estimates of $15.66 million. On average, analysts expect that EyePoint Pharmaceuticals will post -2.57 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of EyePoint Pharmaceuticals during the 3rd quarter valued at about $30,000. GSA Capital Partners LLP acquired a new position in EyePoint Pharmaceuticals in the 3rd quarter valued at approximately $66,000. Wedbush Securities Inc. purchased a new stake in EyePoint Pharmaceuticals in the 3rd quarter worth approximately $42,000. Principal Financial Group Inc. purchased a new stake in EyePoint Pharmaceuticals in the 2nd quarter worth approximately $26,000. Finally, Bridgeway Capital Management Inc. boosted its stake in shares of EyePoint Pharmaceuticals by 40.3% during the 2nd quarter. Bridgeway Capital Management Inc. now owns 714,200 shares of the company’s stock valued at $541,000 after buying an additional 205,000 shares during the period. Hedge funds and other institutional investors own 42.42% of the company’s stock.
EyePoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis.
Further Reading: What is a Fiduciary?
Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.